Humacyte, Inc. (NASDAQ:HUMA) Short Interest Down 6.2% in January

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 24,040,000 shares, a decline of 6.2% from the January 15th total of 25,640,000 shares. Based on an average trading volume of 4,330,000 shares, the short-interest ratio is presently 5.6 days. Approximately 23.0% of the company's shares are sold short.

Hedge Funds Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in HUMA. SG Americas Securities LLC bought a new position in Humacyte during the 3rd quarter worth about $174,000. Wealth Effects LLC bought a new position in Humacyte during the 3rd quarter worth about $349,000. Private Advisor Group LLC increased its holdings in Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company's stock worth $2,030,000 after purchasing an additional 6,510 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company's stock worth $125,000 after purchasing an additional 8,965 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in Humacyte during the 3rd quarter worth about $75,000. Institutional investors own 44.71% of the company's stock.

Humacyte Stock Down 5.5 %

Shares of HUMA traded down $0.21 during trading hours on Friday, reaching $3.55. The stock had a trading volume of 1,624,460 shares, compared to its average volume of 2,141,699. Humacyte has a 52 week low of $2.81 and a 52 week high of $9.97. The firm has a 50-day moving average of $4.44 and a 200 day moving average of $5.15. The company has a market cap of $446.17 million, a P/E ratio of -2.65 and a beta of 1.30.

Analyst Ratings Changes

Several analysts have commented on the stock. D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of Humacyte in a research report on Tuesday, January 21st. Benchmark upped their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, December 23rd. Finally, HC Wainwright restated a "buy" rating and issued a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.